Tomasovic, Luke M.
Liu, Kathy
VanDyke, Derek
Fabilane, Charina S.
Spangler, Jamie B. http://orcid.org/0000-0001-8187-3732
Funding for this research was provided by:
Allegheny Health Network
Gabrielle's Angel Foundation for Cancer Research
National Science Foundation (2143160)
Foundation for the National Institutes of Health (T32 GM136577)
Johns Hopkins-AstraZeneca Scholar award
Achievement Rewards for College Scientists Foundation
Article History
Accepted: 18 October 2023
First Online: 24 November 2023
Declarations
:
: This work was supported by funding from an Allegheny Health Network-Johns Hopkins Research Award (to Jamie B. Spangler), a Gabrielle’s Angel Foundation award (to Jamie B. Spangler), and a National Science Foundation CAREER award (2143160 to Jamie B. Spangler). Luke M. Tomasovic is supported by the NIH Medical Scientist Training Program (T32 GM136577). Derek VanDyke is supported by a Johns Hopkins-AstraZeneca Scholar award, an ARCS<sup>®</sup> Foundation Metro-Washington Chapter Scholar award, and a National Science Foundation Graduate Research Fellowship Program award. Charina S. Fabilane is supported by NIH T32 GM135131.
: Derek VanDyke and Jamie B. Spangler are listed as co-inventors on a patent describing a Treg-biased IL-2-based therapy (International Publication Number WO2020264318A1). Luke M. Tomasovic, Kathy Liu, and Charina S. Fabilane have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors wrote and revised the final manuscript.